Pharmafile Logo

Comirnaty

The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Comirnaty in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Comirnaty.

7

Global Revenue Ranking

Recent articles on PMLiVE featuring Comirnaty

- PMLiVE
FDA approves Pfizer and BioNTech’s jab for COVID-19

Globally, five billion doses of the companies’ vaccine have been distributed

- PMLiVE
JCVI announces advice for autumn COVID-19 vaccination programme eligibility

The Committee has advised offering the vaccine to those at high risk of serious disease

- PMLiVE
BioNTech shares promising results for mRNA immunotherapy candidate in advanced melanoma

Melanoma is currently responsible for around 58,000 deaths globally every year

- PMLiVE
Pfizer/BioNTech’s Omicron JN.1-adapted COVID-19 vaccine approved by MHRA

The UK regulator has approved four versions of the updated vaccine for adults and children from infancy

- PMLiVE
Pfizer/BioNTech’s Omicron JN.1-adapted COVID-19 vaccine recommended by CHMP

The vaccine generated an improved response against several Omicron JN.1 sublineages

- PMLiVE
Pfizer/BioNTech’s COVID-19 vaccine available to buy in UK following MHRA endorsement

The XBB.1.5-adapted vaccine will be available for purchase from March 2024

- PMLiVE
Pfizer and BioNTech’s XBB.1.5-adapted COVID-19 vaccine approved by MHRA

The updated vaccine proved effective against the currently circulating XBB.1.5 subvariant

- PMLiVE
Bavarian Nordic’s COVID-19 booster ‘not suitable’ for emerging variants

Results showed that ABNCoV2 was not as effective against the circulating XBB.1.5 variant

- PMLiVE
Pfizer and BioNTech’s XBB.1.5-adapted COVID-19 vaccine approved by EC

The vaccine is approved for use in adults, children and infants over six months

- PMLiVE
Pfizer and BioNTech’s XBB.1.5-adapted COVID-19 vaccine recommended by CHMP

Doses will be ready to ship immediately upon authorisation by the European Commission

- PMLiVE
MHRA authorises HIPRA Human Health’s COVID-19 vaccine for use in UK

Bimervax is the ninth COVID-19 vaccine to be authorised by the UK medicines regulator

- PMLiVE
BioNTech reveals plans to spend about €1bn more on research and development this year

The company has already started clinical trials assessing four new infectious disease vaccines

Data provided by GlobalData

GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.

Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.

To find out more about how our research and insights can help you, please visit  https://www.globaldata.com/who-we-are/why-globaldata/

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links